Fatty Acid Synthesis Pathway

Fatty acid synthesis, or de novo lipogenesis, is the process your body uses to build new fatty acids from simple precursors. For medical students, mastering this pathway is essential, as it sits at the crossroads of metabolism, linking carbohydrate and fat metabolism. Its dysregulation is a core feature in metabolic diseases like obesity, type 2 diabetes, and non-alcoholic fatty liver disease, making it a high-yield topic for the MCAT and your future clinical practice.

The Starting Point: Acetyl-CoA and its Compartment Problem

The fundamental building block for fatty acids is acetyl-CoA. However, a major logistical challenge exists: acetyl-CoA is produced primarily inside the mitochondria from pyruvate oxidation and beta-oxidation, but fatty acid synthesis occurs in the cytoplasm. The mitochondrial membrane is impermeable to acetyl-CoA.

The solution is the citrate shuttle. Here’s the step-by-step transport mechanism:

1. Inside the mitochondria, acetyl-CoA condenses with oxaloacetate to form citrate, catalyzed by citrate synthase.
2. Citrate is transported out of the mitochondria and into the cytoplasm via a specific transporter.
3. In the cytoplasm, the enzyme ATP-citrate lyase cleaves citrate back into acetyl-CoA and oxaloacetate. The cytoplasmic acetyl-CoA is now ready for use.
4. The oxaloacetate is converted back to malate and then to pyruvate by malic enzyme. This last step generates NADPH, which will be crucial later.

This shuttle elegantly solves the compartment issue and contributes to the reducing power needed for synthesis.

Committing to Synthesis: The Rate-Limiting Step

Before elongation can begin, acetyl-CoA must be "activated." This commitment step is catalyzed by the key regulatory enzyme acetyl-CoA carboxylase (ACC). ACC adds a carboxyl group to acetyl-CoA, using ATP and a biotin cofactor, to form malonyl-CoA.

$$\text{Acetyl-CoA}+{\text{CO}}_2+\text{ATP}\underset{\text{Biotin}}{\overset{\text{Acetyl-CoA Carboxylase (ACC)}}{\to }}\text{Malonyl-CoA}+\text{ADP}+{\text{P}}_i$$

The formation of malonyl-CoA is irreversible and represents the first dedicated step toward fatty acid synthesis. ACC is the primary point of regulation for the entire pathway, controlled allosterically, by phosphorylation, and through transcriptional mechanisms. Its activity signals that energy is abundant.

The Fatty Acid Synthase Complex: An Assembly Line for Palmitate

The fatty acid synthase (FAS) complex is a large, multi-enzyme protein that performs all subsequent reactions. In humans, it is a dimer with two identical subunits, each containing all enzymatic activities. Think of it as a highly efficient molecular assembly line. The end product is typically the 16-carbon saturated fatty acid, palmitate. The process involves four repeating steps: condensation, reduction, dehydration, and a second reduction.

Step 1: Loading. An acetyl group is transferred from acetyl-CoA to the acyl carrier protein (ACP) domain of FAS. A malonyl group from malonyl-CoA is loaded onto the ACP of the other subunit.

Step 2: Condensation. The beta-ketoacyl-ACP synthase (KS) domain catalyzes the condensation of the acetyl and malonyl groups, releasing CO${}_2$ and forming a 4-carbon beta-ketoacyl-ACP. The loss of CO${}_2$ drives this reaction forward.

Step 3: First Reduction. The beta-ketoacyl-ACP is reduced by beta-ketoacyl-ACP reductase, using NADPH as the electron donor, to form a beta-hydroxyacyl-ACP.

Step 4: Dehydration. The beta-hydroxyacyl-ACP undergoes dehydration by hydroxyacyl-ACP dehydratase, creating a trans-2-enoyl-ACP (a double bond).

Step 5: Second Reduction. The enoyl-ACP reductase reduces the double bond, using a second NADPH, to form a saturated acyl-ACP that is now two carbons longer.

This cycle repeats seven times. In each new cycle, the growing acyl chain is transferred back to the KS domain, and a new malonyl-CoA is loaded onto the ACP. After seven cycles, a 16-carbon palmitoyl-ACP is synthesized. Finally, a thioesterase domain cleaves it, releasing free palmitate.

The Essential Role of NADPH

Fatty acid synthesis is a reductive process. For each two-carbon unit added from malonyl-CoA, the pathway consumes two molecules of NADPH—one for each reduction step in the FAS cycle. Therefore, to synthesize one molecule of palmitate (16 carbons), you need 14 NADPH total: 2 NADPH per cycle for 7 cycles.

Where does this NADPH come from? There are two primary sources:

1. The Pentose Phosphate Pathway (PPP): This is the major supplier. The oxidative phase of the PPP, catalyzed by glucose-6-phosphate dehydrogenase (G6PD), generates NADPH. This directly links high blood glucose (and thus high glycolytic flux) to the capacity for fatty acid synthesis.
2. The Citrate Shuttle (Malic Enzyme): As noted earlier, the conversion of malate to pyruvate by malic enzyme in the cytoplasm also produces NADPH, making the shuttle doubly functional.

Hormonal and Allosteric Regulation

The pathway is tightly regulated to match the body's energy state. It is activated in the fed state (high insulin, low glucagon) and suppressed in the fasted state (low insulin, high glucagon).

• Acetyl-CoA Carboxylase (ACC) Regulation:
• Allosteric Activation by Citrate: High cytoplasmic citrate signals ample acetyl-CoA and ATP availability. Citrate allosterically activates ACC.
• Allosteric Inhibition by Palmitoyl-CoA: The end product provides feedback inhibition.
• Phosphorylation/Dephosphorylation: In the fasted state, glucagon-triggered cAMP activates protein kinase A (PKA), which phosphorylates and inactivates ACC. In the fed state, insulin activates protein phosphatases that dephosphorylate and activate ACC. AMP-activated protein kinase (AMPK), activated by low energy (high AMP), also phosphorylates and inhibits ACC.

• Long-term Regulation: A high-carbohydrate diet increases the transcription of enzymes like ACC and FAS, preparing the body for increased lipid synthesis.

Common Pitfalls

1. Confusing Locations for Anabolism vs. Catabolism: A classic MCAT trap is mixing up the cellular compartments. Remember: Fatty Acid Synthesis (anabolism) is cytoplasmic. Fatty Acid Oxidation (catabolism; beta-oxidation) is mitochondrial. Keep "synthesis outside, breakdown inside" as a starting mnemonic.

1. Misidentifying the Carbon Donor and Reducing Agent: It's easy to think acetyl-CoA is directly added. The active elongating unit is actually malonyl-CoA. Similarly, the reducing agent is NADPH, not NADH. NADH is primarily for energy production in oxidative phosphorylation, while NADPH is reserved for reductive biosynthesis (like fatty acid and cholesterol synthesis).

1. Overlooking the Role of the Citrate Shuttle: Don't just memorize "acetyl-CoA is the substrate." You must explain how mitochondrial acetyl-CoA becomes cytoplasmic acetyl-CoA. The citrate shuttle is a frequently tested concept that integrates the TCA cycle with lipid synthesis.

1. Forgetting the CO${}_2$ in Malonyl-CoA: When ACC adds CO${}_2$ to acetyl-CoA, it's not immediately lost. This CO${}_2$ is released during the condensation step on FAS. This "investment and loss" mechanism makes the condensation reaction thermodynamically favorable. The CO${}_2$ is not incorporated into the final fatty acid.

Summary

• Fatty acid synthesis is a cytoplasmic process that builds palmitate from acetyl-CoA, primarily in the liver and adipose tissue during periods of energy excess.
• The citrate shuttle transports mitochondrial acetyl-CoA to the cytoplasm as citrate, which is then cleaved to release acetyl-CoA and generate some NADPH.
• The committed, rate-limiting step is the conversion of acetyl-CoA to malonyl-CoA by acetyl-CoA carboxylase (ACC), a highly regulated enzyme.
• The fatty acid synthase (FAS) complex acts as an assembly line, repeatedly adding two-carbon units from malonyl-CoA in a cycle of condensation, reduction, dehydration, and reduction to build a 16-carbon palmitate chain.
• The process is heavily dependent on NADPH as a reducing agent, supplied mainly by the pentose phosphate pathway and the malic enzyme reaction.
• Regulation is coordinated by insulin and glucagon, with ACC being activated by insulin (dephosphorylation) and citrate, and inhibited by glucagon (phosphorylation), AMPK, and the end-product palmitoyl-CoA.